Use of Cinnamomum Verum for Induction of Labor. Double Blind Randomized Clinical Trial

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age14-45
SponsorUniversidad Nacional Autonoma de Honduras

About this trial

The purpose of the research protocol is to evaluate the effectiveness of Cinnamomum verum extract for the initiation of labor. Cinnamaldehyde ((E)-3-Phenylprop-2-enal) is an α, β unsaturated aromatic aldehyde, derived from cinnamon (Cinnamomum Verum oil) used as a flavoring; It is a clear yellowish liquid substance, with a strong odor and flavor. It is the main component of cinnamon (63%), giving it its physicochemical properties. Cinnamon has been an element of empirical use for the beginning of labor, however, its effectiveness has not been demonstrated.

Cinnamon has been reported for its ethnopharmacological properties in pregnancy, being used to facilitate childbirth, as a lactagogue and for postpartum recovery. In Honduras, its use has been reported to relieve nausea and vomiting during pregnancy, to reduce abdominal pain. , reduction of lower limb edema, to relieve anxiety during labor, as well as a lactagogue without convergent opinions.

Eligibility criteria

Qualifiers

Delivery of an informed consent form signed and dated by parents or guardian and patient

Declared willingness to comply with all study procedures and availability for the duration of the study.

provision of appropriate consent and assent

Willingness and ability to participate in study procedures

Disqualifiers

Current use of antihypertensive or hypoglycemic medications

Presence of non-curable chronic diseases prior to pregnancy or during pregnancy such as hypertension, diabetes, hypothyroidism

Premature rupture of membranes

Infections (urinary tract infection, chorioamnionitis) present at the time of the study (diagnosed with symptoms or leukocytes >12,500 or pathological urine examination)

Trial design

Treatments tested in this trial

  • Cinnamomum Verum oil extract
  • Placebo

Treatment groups

70 Participants
are divided into 2 treatment groups